HAIKOU CITY, China, May 13 /PRNewswire-Asia-FirstCall/ -- China Pharma
Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading
fully-integrated specialty pharmaceuticals company in China, today announced
that the Company's Chief Executive Officer and President, Ms. Zhilin Li, has
been invited to be a speaker on a panel at the Brean Murray, Carret & Co. (BMC)
2010 Life Sciences Summit.
Brean Murray, Carret & Co. 2010 Life Sciences Summit will be held on Monday, May 17, 2010 at the Grand Hyatt Hotel in New York City. Ms. Li is scheduled to be one of five speakers on the "Winners and Losers of China Healthcare Reform" panel at 2:00 pm ET. The discussion will highlight the unprecedented $124 billion healthcare reform in China, and the opportunities for and potential impact on a range of participants in the healthcare industry.
Ms. Li will be available to meet with institutional investors throughout the conference. For further details, please contact your respective institutional sales representative.
"I am honored to be invited as a panel speaker at BMC's 2010 Life Sciences Summit to discuss China's healthcare reform with industrial professionals, entrepreneurs and the investment community," said Ms. Zhilin Li, CEO and president of China Pharma, "I look forward to having an in-depth discussion with other industry experts on incremental government healthcare reform expenditure, essential drug list (EDL) and medical insurance, and corresponding strategies to capitalize on these new opportunities. We expect the impact of the reform to be significant to the pharmaceutical industry in the coming years. We will remain nimble to enhance our execution strategy as needed in response to the new environment when it becomes a reality."
As a founder of Hainan Helpson Medical & Biotechnology Co., Ltd., (a wholly owned subsidiary of CPHI), Ms. Li has demonstrated in-depth knowledge of the Chinese pharmaceutical market, and distinguished capabilities to design and execute strategies during the past 17 years of leading the Company.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
Advertisement
Brean Murray, Carret & Co. 2010 Life Sciences Summit will be held on Monday, May 17, 2010 at the Grand Hyatt Hotel in New York City. Ms. Li is scheduled to be one of five speakers on the "Winners and Losers of China Healthcare Reform" panel at 2:00 pm ET. The discussion will highlight the unprecedented $124 billion healthcare reform in China, and the opportunities for and potential impact on a range of participants in the healthcare industry.
Advertisement
Ms. Li will be available to meet with institutional investors throughout the conference. For further details, please contact your respective institutional sales representative.
"I am honored to be invited as a panel speaker at BMC's 2010 Life Sciences Summit to discuss China's healthcare reform with industrial professionals, entrepreneurs and the investment community," said Ms. Zhilin Li, CEO and president of China Pharma, "I look forward to having an in-depth discussion with other industry experts on incremental government healthcare reform expenditure, essential drug list (EDL) and medical insurance, and corresponding strategies to capitalize on these new opportunities. We expect the impact of the reform to be significant to the pharmaceutical industry in the coming years. We will remain nimble to enhance our execution strategy as needed in response to the new environment when it becomes a reality."
As a founder of Hainan Helpson Medical & Biotechnology Co., Ltd., (a wholly owned subsidiary of CPHI), Ms. Li has demonstrated in-depth knowledge of the Chinese pharmaceutical market, and distinguished capabilities to design and execute strategies during the past 17 years of leading the Company.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
Phone: +86-898-6681-1730 (China)
Email: [email protected]
CCG Investor Relations
Lei Huang, Account Manager
Phone: +1-646-833-3417 (New York)
Email: [email protected]
Vivian Chen, Sr. Market Intelligence Exec.
Phone: +1-646-701-7445(New York)
Email: [email protected]
SOURCE China Pharma Holdings, Inc.